Literature DB >> 23003923

The biologically effective dose in inhalation nanotoxicology.

Ken Donaldson1, Anja Schinwald, Fiona Murphy, Wan-Seob Cho, Rodger Duffin, Lang Tran, Craig Poland.   

Abstract

In all branches of toxicology, the biologically effective dose (BED) is the fraction of the total dose of a toxin that actually drives any toxic effect. Knowledge of the BED has a number of applications including in building structure-activity relationships, the selection of metrics, the design of safe particles, and the determination of when a nanoparticle (NP) can be considered to be "new" for regulatory purposes. In particle toxicology, we define the BED as "the entity within any dose of particles in tissue that drives a critical pathophysiogically relevant form of toxicity (e.g., oxidative stress, inflammation, genotoxicity, or proliferation) or a process that leads to it." In conventional chemical toxicology, researchers generally use the mass as the metric to describe dose (such as mass per unit tissue or cells in culture) because of its convenience. Concentration, calculated from mass, may also figure in any description of dose. In the case of a nanoparticle dose, researchers use either the mass or the surface area. The mass of nanoparticles is not the only driver of their activity: the surfaces of insoluble particles interact with biological systems, and soluble nanoparticles can release factors that interact with these systems. Nanoparticle shape can modify activity. In this Account, we describe the current knowledge of the BED as it pertains to different NP types. Soluble toxins released by NPs represent one potential indicator of BED for wholly or partially soluble NPs composed of copper or zinc. Rapid dissolution of these NPs into their toxic ions in the acidic environment of the macrophage phagolysosome causes those ions to accumulate, which leads to lysosome destabilization and inflammation. In contrast, soluble NPs that release low toxicity ions, such as magnesium oxide NPs, are not inflammogenic. For insoluble NPs, ζ potential can serve as a BED measurement because the exposure of the particle surface to the acidic milieu of the phagolysosome and interactions with the lysosomal membrane can compromise the integrity of the NPs. Researchers have explored oxidative potential of NPs most extensively as an indicator of the BED: the ability of an NP to cause oxidative stress in cells is a key factor in determining cell toxicity, inflammogenicity, and oxidative DNA adduct formation. Finally we discuss BEDs for high aspect ratio nanoparticles because long fibers or nanoplatelets can cause inflammation and further effects. These consequences arise from the paradoxically small aerodynamic diameter of fibers or thin platelets. As a result, these NPs can deposit beyond the ciliated airways where their extended dimensions prevent them from being fully phagocytosed by macrophages, leading to frustrated phagocytosis. Although knowledge is accumulating on the BED for NPs, many questions and challenges remain in understanding and utilizing this important nanotoxicological parameter.

Entities:  

Mesh:

Year:  2012        PMID: 23003923     DOI: 10.1021/ar300092y

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  39 in total

1.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

2.  Lung biodurability and free radical production of cellulose nanomaterials.

Authors:  Aleksandr B Stefaniak; Mohindar S Seehra; Natalie R Fix; Stephen S Leonard
Journal:  Inhal Toxicol       Date:  2014-10       Impact factor: 2.724

Review 3.  Characterization of engineered TiO₂ nanomaterials in a life cycle and risk assessments perspective.

Authors:  Véronique Adam; Stéphanie Loyaux-Lawniczak; Gaetana Quaranta
Journal:  Environ Sci Pollut Res Int       Date:  2015-05-22       Impact factor: 4.223

Review 4.  The impact of nanomaterial characteristics on inhalation toxicity.

Authors:  Frank S Bierkandt; Lars Leibrock; Sandra Wagener; Peter Laux; Andreas Luch
Journal:  Toxicol Res (Camb)       Date:  2018-02-01       Impact factor: 3.524

5.  Identification of TGF-β receptor-1 as a key regulator of carbon nanotube-induced fibrogenesis.

Authors:  Anurag Mishra; Todd A Stueckle; Robert R Mercer; Raymond Derk; Yon Rojanasakul; Vincent Castranova; Liying Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-21       Impact factor: 5.464

Review 6.  Characterizing risk assessments for the development of occupational exposure limits for engineered nanomaterials.

Authors:  P A Schulte; E D Kuempel; N M Drew
Journal:  Regul Toxicol Pharmacol       Date:  2018-03-21       Impact factor: 3.271

7.  Shape affects the interactions of nanoparticles with pulmonary surfactant.

Authors:  Xubo Lin; Yi Y Zuo; Ning Gu
Journal:  Sci China Mater       Date:  2015-01-20       Impact factor: 8.273

8.  Cell-based assays that predict in vivo neurotoxicity of urban ambient nano-sized particulate matter.

Authors:  Hongqiao Zhang; Amin Haghani; Amirhosein H Mousavi; Mafalda Cacciottolo; Carla D'Agostino; Nikoo Safi; Mohammad H Sowlat; Constantinos Sioutas; Todd E Morgan; Caleb E Finch; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2019-09-19       Impact factor: 7.376

9.  Inhalation Exposure to Carbon Nanotubes (CNT) and Carbon Nanofibers (CNF): Methodology and Dosimetry.

Authors:  Günter Oberdörster; Vincent Castranova; Bahman Asgharian; Phil Sayre
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2015       Impact factor: 6.393

10.  Biokinetics of Nanomaterials: the Role of Biopersistence.

Authors:  Peter Laux; Christian Riebeling; Andy M Booth; Joseph D Brain; Josephine Brunner; Cristina Cerrillo; Otto Creutzenberg; Irina Estrela-Lopis; Thomas Gebel; Gunnar Johanson; Harald Jungnickel; Heiko Kock; Jutta Tentschert; Ahmed Tlili; Andreas Schäffer; Adriënne J A M Sips; Robert A Yokel; Andreas Luch
Journal:  NanoImpact       Date:  2017-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.